Application of kdm6b protein in breast cancer prognosis assessment kit and diagnostic kit

Abstract

The invention provides the application of KDM6B protein in breast cancer prognosis assessment kit and diagnosis kit, and belongs to the field of biotechnology. It solves the urgent need to provide new markers for the diagnosis and treatment of breast cancer, and to find the prognostic genes and / or proteins of breast cancer (especially triple-negative breast cancer). In the application, KDM6B protein is used as a molecular marker, and KDM6B monoclonal antibody or KDM6B polyclonal antibody is used in combination with experimental reagents to detect the relative expression of KDM6B protein in breast cancer tissues. The invention has the advantages that the KDM6B protein can be used as a molecular marker to detect its expression level and can be used to guide the prognosis judgment of breast cancer and the like.

Description

technical field [0001] The invention belongs to the field of biotechnology, and particularly relates to the application of KDM6B protein in breast cancer prognosis assessment kits and diagnostic kits. Background technique [0002] Breast cancer is the most common malignant tumor in women, and its incidence worldwide is second only to lung cancer. It is estimated that more than 1.2 million women are diagnosed with breast cancer every year. The incidence of breast cancer in our country has risen to be the first among female malignant tumors, and the death rate is the fifth, becoming one of the biggest threats to women's health. The early symptoms of breast cancer are not obvious, and it is already in the middle and late stage when it is diagnosed. Although after surgery, chemotherapy, and radiotherapy, the curative effect of many breast cancer patients is not satisfactory. Early diagnosis and treatment and prognosis assessment of breast cancer are the key to improving the sur...

AI Technical Summary

Problems solved by technology

[0005] The classification of breast cancer is relatively complicated, especially triple-negative breast cancer lacks effective clinical treatment targets, and the prognosis is extremely poor, so it is difficult to find effective indicators to reasonably evaluate the treatment effect and prognosis of different types of breast cancer

At present, little is known about the role of KDM6B in breast cancer, and the expression of KDM6B in breast cancer tissues of different types is still unclear. The application of KDM6B expression in breast cancer cells in the prognosis of patients has not been reported yet.

Images